drugset / Trial / NCT02357797

Adjunctive Vortioxetine in Schizophrenia

NCT02357797

Phase 4 Unknown 88 enrolled Northwell Health Takeda · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a 16-week, randomized, double-blind, parallel group, placebo-controlled study comparing adjunctive vortioxetine with identically appearing adjunctive placebo pills in 88 stable patients with a research diagnosis of schizophrenia determined with the Structured Clinical Interview for DSM (SCID). Patient randomization will be stratified by illness duration (i.e., \</=5 years and \>5 years) in order to allow for post-hoc analyses examining whether earlier illness moderates greater negative and /or cognitive symptom reduction in response to vortioxetine.

Timeline

Start
2016-02
Primary completion
2023-10-01
Completion
2024-06-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Vortioxetine Unknown 20 mg

Indications